Orion pharmaceutical research earmarked for EIB money

Published: 14-Aug-2009
Research & Development

EIB to lend Orion Euro 75m to help pharmaceutical research and development work


The European Investment Bank (EIB) is planning to lend Finland's Orion Euro 75m to help it stage pharmaceutical research and development work from this year to 2012.

Part of a â"šÂ¬300m programme, the work would be carried out within Orion's existing r&d facilities, laboratories, pilot plants and clinical centres.

  • Companies:
  • Orion Group
See more

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Read more
Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)
Research & Development

Orion and MSD announce two Phase III trials to evaluate ODM-208/MK5684 in patients with metastatic castration-resistant prostate cancer

OMAHA1 and OMAHA2a are the first Phase III trials to be initiated for ODM-208/MK5684
Research & Development

Orion and MSD announce global collaboration to develop and commercialise ODM-208

Agreement strengthens and complements MSD’s oncology pipeline
Drug Delivery

Nanoform and Orion collaborate on next-generation drug development

This collaboration will utilise Nanoform’s proprietary CESS technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development
Research & Development

In the pursuit of new medicines for oncological diseases

The Wisconsin Technology Innovation Initiative (Wi2) and Orion Corporation have announced a new strategic collaboration
Research & Development

Endo and Orion agree collaboration deal

Will bring forward eight drug candidates and share development costs
Drug Delivery

DelSiTech in research collaboration with Orion

Sign agreement that will enable Orion to apply DelSiTech proprietary drug delivery technology
Subscribe now